Table 3.

Correlation of Baseline SUV Values with Treatment Outcomes

Variable	Endpoint	Events/total	Hazard ratio (95% CI)	p-value
Primary SUVmax (> vs. ≤ median)	Local relapse	0/34 vs. 8/34	Cannot estimate
	Local-regional relapse	4/34 vs. 12/34	0.31 (0.10, 0.97)	0.04
	Distant metastasis	2/34 vs. 6/34	0.32 (0.06, 1.57)	0.16
	Progression-free survival	6/34 vs. 18/34	0.30 (0.12, 0.75)	0.01
	Overall survival	4/34 vs. 11/34	0.38 (0.12, 1.20)	0.10
Nodal SUVmax (> vs. ≤ median)	Regional relapse	6/32 vs. 7/33	0.89 (0.30, 2.66)	0.84
	Local-regional relapse	6/32 vs. 9/33	0.72 (0.26, 2.05)	0.54
	Distant metastasis	2/32 vs. 5/33	0.40 (0.08, 2.05)	0.27
	Progression-free survival	8/32 vs. 15/33	0.56 (0.24, 1.33)	0.19
	Overall survival	4/32 vs. 10/33	0.44 (0.14, 1.39)	0.16
Primary SUVpeak (> vs. ≤ median)	Local relapse	1/34 vs. 7/34	0.15 (0.02, 1.23)	0.08
	Local-regional relapse	6/34 vs. 10/34	0.60 (0.22, 1.65)	0.32
	Distant metastasis	3/34 vs. 5/34	0.62 (0.15, 2.62)	0.52
	Progression-free survival	9/34 vs. 15/34	0.62 (0.27, 1.42)	0.25
	Overall survival	5/34 vs. 10/34	0.55 (0.19, 1.62)	0.28
Nodal SUVpeak (> vs. ≤ median)	Regional relapse	6/32 vs. 7/33	0.93 (0.31, 2.77)	0.90
	Local-regional relapse	6/32 vs. 9/33	0.75 (0.27, 2.13)	0.59
	Distant metastasis	3/32 vs. 4/33	0.81 (0.18, 3.63)	0.79
	Progression-free survival	9/32 vs. 14/33	0.74 (0.32, 1.72)	0.49
	Overall survival	5/32 vs. 9/33	0.61 (0.20, 1.82)	0.37

CI = confidence interval.

Hazard ratios estimated from Cox models.